RPG Life Sciences transfers API biz to subsidiary, brings in PE investors, acquires Actis

Listed Co AcquisitionMarquee Jv AnnouncedStrategic Transactions View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.8%1-day move

₹2847.40

prior close

₹2863.40

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.3+0.4-0.9—-2.8-3.1-4.0-4.3-6.6-7.4-6.8———

Up moveDown movePending

AI summary

RPG Life Sciences has transferred its API business to a wholly owned subsidiary, RPG Active Pharma, for about Rs. 33.55 crore on a slump sale basis. PE funds India Life Sciences Fund IV and Vistaject Fund will invest Rs. 243.33 crore (with aggregate commitment up to Rs. 700 crore) for around 40% stake in RPGAP. RPGAP will separately acquire 100% of Actis Generics Private Limited for Rs. 80 crore in cash. The API segment contributed 13.54% of FY26 consolidated revenue. The restructuring allows sharper focus on the Formulations business and funds growth in the API segment.

Likely market impact

Restructuring separates API from formulations, brings marquee PE investors on board, and adds scale via Actis Generics acquisition.